Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol
01 Pubblicazione su rivista
La Rocca U., Perrone M. P., Piciocchi A., Cinti P., Barberi W., Gozzer M., Baftii M. S., Torelli G. F., Quattrocchi L., Gesuiti P., Lattanzi R., Cavallari C., Ricci R., Laurenti L., Foa R., Girelli G., Iori A. P.
ISSN: 0268-3369
The role of antibodies directed against the human leukocyte antigen (HLA) system has been well analyzed in rejection of solid organ transplantations [1, 2] and in transfusion medicine [3]. In the setting of allogeneic hematopoietic stem cells transplantation (HSCT), only in the recent years their importance has been better defined, even though antiHLA antibodies are frequently detectable in hematologic
patients, due to sensitization from multiple transfusions, usually before the introduction of online universal leukoreduction, previous transplantations, and pregnancies in female patients.